Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
17.43-0.04 (-0.23%)
At close: 04:00PM EST
16.51 -0.92 (-5.28%)
Pre-market: 08:19AM EST

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120
https://www.iovance.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Frederick G. Vogt Esq., J.D., Ph.D.Interim CEO, President, General Counsel & Corporate Secretary1.39MN/A1974
Mr. Jean-Marc Bellemin M.B.A.CFO, Principal Accounting Officer & Treasurer932.2kN/A1973
Dr. Igor P. BilinskyChief Operating Officer932.2kN/A1973
Dr. Friedrich Graf Finckenstein M.D.Chief Medical Officer1.06MN/A1967
Ms. Sara PellegrinoVice President of Investor Relations & Public RelationsN/AN/AN/A
Ms. Tracy WintonSenior Vice President of Human ResourcesN/AN/AN/A
Mr. Howard B. Johnson M.B.A.Chief Business OfficerN/AN/A1960
Mr. James Ziegler M.B.A.Executive Vice President of CommercialN/AN/AN/A
Dr. Raj K. Puri M.D., Ph.D.Executive VP of Regulatory Strategy & Translational MedicineN/AN/AN/A
Mr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Corporate governance

Iovance Biotherapeutics, Inc.’s ISS governance QualityScore as of 28 February 2024 is 6. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.